| Your Current Location : Fund Card : Portfolio Classification |
 |
|
|
| |
| Baroda BNP Paribas Health and Wellness Fund IDCW Direct |
| [Equity: Sectoral] |
|
| |
|
|
| Instruments Breakdown |
| Instruments |
Composition |
| Current Asset |
-0.14 |
| Equity |
97.26 |
| Trep |
2.88 |
|
| |
| Concentration Analysis |
| Top 5 Holdings |
31.22% |
| Top 10 Holdings |
52.94% |
| Top 25 Holdings |
88.87% |
|
|
|
| |
| Sector Analysis |
| Sector/Ratings |
Net Asset(%) |
| Pharma & Biotech |
67.79 |
| Healthcare |
18.98 |
| Miscellaneous |
7.29 |
| Cash |
2.74 |
| Retail |
1.64 |
| Software & Services |
1.56 |
|
|
|
|
|
| Portfolio Metrics |
|
| PB Ratio |
6.64 |
| PE Ratio |
44.32 |
|
| |
| Top 25 Holdings |
|
|
| Holdings |
Net Asset(%) |
| Sun Pharmaceutical Industries Limited |
9.38 |
| Lupin Limited |
6.09 |
| IPCA Laboratories Limited |
5.34 |
| Abbott India Limited |
5.28 |
| Torrent Pharmaceuticals Limited |
5.13 |
| Laurus Labs Limited |
4.78 |
| Fortis Health Care Ltd |
4.35 |
| Apollo Hospitals Enterprise Limited |
4.32 |
| J B Chemicals and Pharma Ltd |
4.24 |
| Astra IDL Ltd. |
4.03 |
| Emcure Pharmaceuticals Limited |
3.44 |
| SBI Life Insurance Co Ltd |
3.43 |
| (5) Total outstanding exposure in derivative instruments as on April 30, 2026 is Rs. Nil. |
2.97 |
| Clearing Corporation of India Ltd |
2.88 |
| ICICI PRUDENTIAL LIFE INSURA L |
2.81 |
| Glenmark Pharmaceuticals Limited |
2.72 |
| Aurobindo Pharma Limited |
2.62 |
| Dr Lal Path Labs Ltd |
2.58 |
| Gland Pharma Limited |
2.09 |
| DIVI LABORATORIES LTD |
2.07 |
| Ajanta Pharma Limited |
1.86 |
| ACUTAAS CHEMICALS LIMITED |
1.76 |
| MedPlus Health Services Limited |
1.64 |
| Inventurus Knowledge Solutions Limited |
1.56 |
| Nephrocare Health Service Pvt. Ltd. |
1.50 |
|
|
|
| |
|
| |
| Sector Analysis Graphical Mode |
|
| |
|
|
| |
|
 |
| |
|
|
|
